Clinical trials: Mild to Moderate COVID-19
COVID-19
Safety, Tolerability, and Treatment Effect of Belnacasan in Patients With COVID-19
The purpose of this trial is to assess the safety, tolerability and treatment effect of the orally administered Caspase-1 inhibitor, belnacasan, for the treatment of patients with mild to moderate COVID-19 and to generate proof…
- Trial name
- NCT05164120
- Testing
- Belnacasan
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- MedStar Health
SARS-CoV-2 Infection
A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection
This was a Phase 2/3 study to assess the efficacy about therapeutic effect of CT-P59 to the mild to moderate SARS-CoV-2 infected patients and the safety during after study drug injection.
- Trial name
- NCT04602000
- Testing
- CT-P59
- Where
- South Korea
- Volunteers
- 1,642 people
- Sponsor
- Celltrion
Covid19
Use of Hyperbaric Oxygen Therapy to Treat COVID-19 Patients With Respiratory Distress
Investigate whether hyperbaric oxygen therapy treatment can become a viable treatment option for COVID-19. If successful, providers will be able to provide future COVID-19 patients with mild-to-moderate respiratory distress…
- Trial name
- HBOT (NCT04800120)
- Testing
- Hyperbaric Oxygen Therapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Steward St. Elizabeth's Medical Center of Boston, Inc.
Covid19, Diabetes
Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients
This is a randomized, double-blind, placebo-controlled, multi-arm, multicenter, phase II trial design to allow a rapid efficacy and toxicity assessment of potential therapies (camostat mesilate and artemisia annua) immediately…
- Conditions
- Covid19, Diabetes, Hypertension, Obesity
- Trial name
- NCT04530617
- Testing
- Camostat Mesilate, Artemisia Annua Leaf
- Where
- Mexico
- Volunteers
- 246 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
COVID 19 Disease, Mild to Moderate COVID 19 Disease
A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression
A clinical study to assess the efficacy and safety of oral tafenoquine compared to placebo in patients with mild to moderate COVID 19 disease and low risk of disease progression (the "ACLR8-LR" study).
- Conditions
- COVID 19 Disease, Mild to Moderate COVID 19 Disease, SARS-CoV-2, Infectious Disease
- Trial name
- NCT05947812
- Testing
- Tafenoquine Oral Tablet
- Volunteers
- 148 people
- Sponsor
- 60P Australia Pty Ltd
Covid-19
CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients
This is a phase 3, randomized, placebo controlled, double-blind, multicenter, stratified study of CPI-006 plus standard of care (SOC) versus placebo plus SOC in mild to moderately symptomatic hospitalized Covid-19 patients with…
- Trial name
- NCT04734873
- Testing
- CPI-006 2 mg/kg + SOC, CPI-006 1 mg/kg + SOC
- Where
- 91 sites in United States, Argentina and 10 more
- Volunteers
- 46 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
Safety, SARS-CoV2 Infection
Efficacy of Ivermectin in COVID-19
The newly emerged corona virus disease 2019 (COVID-19) has spread to all over the world, with recent estimates of more than 236 million cases diagnosed and led to 4.8 million deaths as November 20211 .Therapeutic approaches are…
- Conditions
- Safety, SARS-CoV2 Infection, Ivermectin Poisoning, Effect of Drug
- Trial name
- NCT05076253
- Testing
- Ivermectin
- Where
- Thailand
- Volunteers
- 72 people
- Sponsor
- Bangkok Metropolitan Administration Medical College and Vajira Hospital
SARS CoV 2 Infection
Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients
This is a phase Ib, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, efficacy and pharmacokinetics of ASC10 tablets in mild or moderate COVID-19 subjects.
- Trial name
- NCT05596045
- Testing
- ASC10
- Where
- 2 sites in United States
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
Mild to Moderate COVID-19
Phase III Clinical Study Evaluating the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19
The study is a multicenter, randomized, double-blind, placebo-controlled efficacy, safety Phase III clinical trial designed to evaluate the efficacy and safety of WPV01 in patients with mild/moderate COVID-19.
- Trial name
- NCT06197217
- Testing
- WPV01
- Where
- China
- Volunteers
- 1,350 people
- Sponsor
- Westlake Pharmaceuticals (Hangzhou) Co., Ltd.
Corona Virus Infection
Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection
This is a multi-center, randomized, controlled, phase II clinical efficacy study evaluating a novel Nitric Oxide Releasing Solution (NORS) treatment for the prevention and treatment of COVID-19 in healthcare workers at risk of…
- Trial name
- NOCOVID (NCT04337918)
- Testing
- NORS (Nitric Oxide Releasing Solution)
- Where
- 5 sites in Canada
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Sanotize Research and Development corp.
Covid19, SARS-CoV2 Infection
Masitinib in Patients With Symptomatic Mild to Moderate COVID-19
The objective of the study is to evaluate the anti-viral efficacy of 3 different dosages of masitinib in patients with symptomatic mild to moderate COVID-19.
- Conditions
- Covid19, SARS-CoV2 Infection, Coronavirus Disease 2019
- Trial name
- NCT05047783
- Testing
- Masitinib Mesylate
- Where
- 6 sites in France, Russia and 1 more
- Volunteers
- 78 people
- Sponsor
- AB Science
COVID-19, Thermotherapy
Local Thermotherapy for Patients With Mild-to-moderate COVID-19
The etiological agent of the current pandemic is a (+)ssRNA virus. SARS-CoV-2 is infecting thousands of people in the world with a fatality rate that varies from 0.1 to 5% in affected countries, thereby causing enormous economic…
- Trial name
- TherMoCoV (NCT04363541)
- Testing
- Electric pad for human external pain therapy
- Where
- 3 sites in Mexico
- Volunteers
- 274 people
- Sponsor
- Instituto Nacional de Perinatologia
COVID-19
A Retrospective Study in Patients With Mild to Moderate COVID-19
The purpose of this retrospective study is to analyze real-world disease progression in mild-moderate COVID-19 patients with at least one risk factor for serve COVID-19 illness or death.
- Trial name
- NCT05374772
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Pudong Hospital
Mild-to-moderate COVID-19
A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19
This randomized, open-label, prospective, parallel-group controlled clinical study that aims to explore the natural history of COVID-19 illness and the safety of KB109, a novel glycan, plus SSC versus SSC alone and measures of…
- Trial name
- NCT04414124
- Testing
- KB109 + Self Supportive Care (SSC), Self Supportive Care (SSC) Alone
- Where
- 16 sites in United States
- Volunteers
- 350 people
- Sponsor
- Kaleido Biosciences
COVID-19
A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.
This phase 2 study is to assess the safety and tolerability of APX-115 active doses compared to placebo following multiple oral dosing in hospitalized patients with confirmed, mild to moderate, symptomatic COVID-19.
- Trial name
- NCT04880109
- Testing
- APX-115
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- Aptabio Therapeutics, Inc.
Covid19
Efficacy and Safety of Ovotransferrin in COVID-19 Patients
Chicken egg consists of three main components, egg white (56%), yolk (33%) and shell (11%). The key component of egg white is 88 percent water and 12 percent solids, of which over 90 percent are protein.
- Trial name
- NCT04643054
- Testing
- Ovotransferrin
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
COVID-19 Pneumonia
Pilot Study of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia
The global pandemic of novel coronavirus disease 2019 (COVID-19) began in Wuhan, China, in December 2019, and has since spread worldwide.
- Trial name
- NCT04709172
- Testing
- Cefditoren pivoxil 400mg
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Meiji Pharma Spain S.A.
COVID-19
A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19
This Phase Ⅱ/Ⅲ study is to evaluate whether or not there is a difference in time recovery of COVID-19 signs and symptoms through Day 29 between SIM0417/ritonavir and placebo.
- Trial name
- NCT05506176
- Testing
- SIM0417
- Where
- 35 sites in China
- Volunteers
- 1,208 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Covid19
Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal
COVID-19 has affected almost all countries in the world. Every other country is constantly working towards its treatment and development of vaccines, with little to no success so far.
- Trial name
- NCT04694612
- Testing
- Favipiravir, Remdesivir
- Where
- 2 sites in Nepal
- Volunteers
- 676 people
- Sponsor
- Nepal Health Research Council
Mild to Moderate COVID-19
Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19
This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of RAY1216 tablets in the treatment of mild to moderate SARS-CoV-2 infection.
- Trial name
- NCT05620160
- Testing
- RAY1216
- Where
- China
- Volunteers
- 1,359 people
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd